Walder Wyss advised Alentis Therapeutics on the deal. Honigman advised Catalio Capital Management. Alentis Therapeutics raised $181.4 million in Series D financing, supported by a syndicate...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised the funds managed by Perceptive Advisors, LLC. SOPHiA GENETICS SA (NASDQ: SOPH), a Swiss data-driven medicine software company, closed a secured term loan...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised CRISPR Therapeutics on the issuance. CRISPR Therapeutics AG (NASDAQ: CRSP), a Switzerland-based biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases,...
You must be a Standard 1 Year member to access this content.
Walder Wyss advised Nasdaq listed Altamira Therapeutics. Altamira Therapeutics Ltd. (Nasdaq: CYTO), a company dedicated to developing therapeutics that address important unmet medical needs, entered into a binding...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised the selling shareholders of RIRI Group in this transaction. Homburger advised OC Oerlikon. Oerlikon, a global innovation provider for surface engineering, polymer...
You must be a Standard 1 Year member to access this content.
Clifford Chance and Niederer Kraft Frey advised Partners Group on the deal. Lenz & Staehelin advised Climeworks. Homburger advised M&G . Partners Group invested in Climeworks,...
You must be a Standard 1 Year member to access this content.
Lenz & Staehelin advised Heubach and SK Capital on this transaction. Homburger advised Clariant. Kirkland & Ellis advised SK Capital Partners on the deal. The Heubach...
You must be a Standard 1 Year member to access this content.
Homburger acted as lead counsel to Colfax Corporation. Lenz & Staehelin and Davis Polk advised the Mathys family as Sellers. DJO, a subsidiary of Colfax Corporation...
You must be a Standard 1 Year member to access this content.
